دورية أكاديمية
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.
| العنوان: | T Regulatory Cells and Priming the Suppressive Tumor Microenvironment. |
|---|---|
| المؤلفون: | Paluskievicz CM; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, United States., Cao X; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States., Abdi R; Division of Renal Medicine, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States., Zheng P; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, United States.; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Liu Y; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, United States.; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, United States., Bromberg JS; Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, United States.; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, United States.; Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2019 Oct 15; Vol. 10, pp. 2453. Date of Electronic Publication: 2019 Oct 15 (Print Publication: 2019). |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Immunomodulation*, Neoplasms/*etiology , Neoplasms/*metabolism , T-Lymphocytes, Regulatory/*immunology , T-Lymphocytes, Regulatory/*metabolism , Tumor Microenvironment/*immunology, Animals ; Biomarkers ; Cell Movement ; Disease Susceptibility/immunology ; Humans ; Ligands ; Lymphocytes, Tumor-Infiltrating ; Neoplasm Metastasis ; Neoplasm Staging ; Protein Binding |
| مستخلص: | Treg play a central role in maintenance of self tolerance and homeostasis through suppression of self-reactive T cell populations. In addition to that role, Treg also survey cancers and suppress anti-tumor immune responses. Thus, understanding the unique attributes of Treg-tumor interactions may permit control of this pathologic suppression without interfering with homeostatic self-tolerance. This review will define the unique role of Treg in cancer growth, and the ways by which Treg inhibit a robust anti-tumor immune response. There will be specific focus placed on Treg homing to the tumor microenvironment (TME), TME formation of induced Treg (iTreg), mechanisms of suppression that underpin cancer immune escape, and trophic nonimmunologic effects of Treg on tumor cells. (Copyright © 2019 Paluskievicz, Cao, Abdi, Zheng, Liu and Bromberg.) |
| References: | PLoS One. 2010 Jul 22;5(7):e11469. (PMID: 20661468) Cell Res. 2018 Apr;28(4):416-432. (PMID: 29472691) Science. 2010 May 7;328(5979):749-52. (PMID: 20339029) Int J Radiat Oncol Biol Phys. 2015 Oct 1;93(2):425-35. (PMID: 26253394) PLoS One. 2011;6(9):e24671. (PMID: 21935436) Immunology. 2008 May;124(1):13-22. (PMID: 18346152) J Exp Med. 2012 Sep 24;209(10):1713-22, S1-19. (PMID: 22966003) Clin Cancer Res. 2006 Sep 15;12(18):5423-34. (PMID: 17000676) J Immunol. 2012 Dec 15;189(12):5590-601. (PMID: 23152566) Blood. 2006 May 15;107(10):3925-32. (PMID: 16418326) Nat Immunol. 2003 Apr;4(4):337-42. (PMID: 12612581) Biochim Biophys Acta. 2013 Dec;1836(2):197-210. (PMID: 23711559) Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10113-8. (PMID: 18635688) Clin Cancer Res. 2009 Oct 15;15(20):6348-57. (PMID: 19825957) Nat Med. 2009 Aug;15(8):930-9. (PMID: 19633656) Lung Cancer. 2010 Mar;67(3):361-5. (PMID: 19487045) J Clin Invest. 2007 May;117(5):1147-54. (PMID: 17476344) Blood. 2005 Nov 1;106(9):3127-33. (PMID: 16037385) Cancer Res. 1992 Dec 15;52(24):6949-52. (PMID: 1458485) Semin Cancer Biol. 2012 Oct;22(5-6):455-61. (PMID: 22627188) J Clin Oncol. 2013 Feb 10;31(5):616-22. (PMID: 23295794) Cancer Res. 2013 Apr 15;73(8):2435-44. (PMID: 23423978) Eur J Immunol. 2009 Sep;39(9):2331-6. (PMID: 19662638) Clin Cancer Res. 2003 Oct 1;9(12):4404-8. (PMID: 14555512) Diabetes. 2012 Jun;61(6):1519-26. (PMID: 22427377) Immunol Rev. 2017 Mar;276(1):80-96. (PMID: 28258692) Clin Cancer Res. 2016 Oct 15;22(20):4973-4978. (PMID: 27582486) Front Immunol. 2018 Sep 25;9:2159. (PMID: 30319622) J Clin Oncol. 2006 Dec 1;24(34):5373-80. (PMID: 17135638) Sci Rep. 2018 Jan 22;8(1):1323. (PMID: 29358632) Immunity. 2007 Oct;27(4):635-46. (PMID: 17919943) Cytokine. 2004 Nov 7;28(3):109-23. (PMID: 15473953) Cancer Immunol Res. 2013 Jul;1(1):32-42. (PMID: 24777248) Immunity. 2016 Feb 16;44(2):316-29. (PMID: 26872697) Immunity. 2009 May;30(5):626-35. (PMID: 19464985) Cancer Immunol Immunother. 2014 Jan;63(1):67-72. (PMID: 24213679) Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7. (PMID: 12218188) PLoS One. 2013 Oct 04;8(10):e76379. (PMID: 24124553) Curr Opin Pharmacol. 2016 Aug;29:7-16. (PMID: 27209048) J Neurol Sci. 2017 Sep 15;380:112-121. (PMID: 28870549) Nat Commun. 2018 Aug 1;9(1):3020. (PMID: 30069025) Nat Commun. 2017 Mar 14;8:14649. (PMID: 28290453) Cell Physiol Biochem. 2017;43(6):2155-2169. (PMID: 29069643) Proc Natl Acad Sci U S A. 2008 Jul 15;105(28):9721-6. (PMID: 18607004) Front Immunol. 2017 Jan 09;7:682. (PMID: 28119694) Trends Cell Biol. 2012 Jan;22(1):50-60. (PMID: 22001186) Int J Clin Exp Pathol. 2013 Aug 15;6(9):1806-16. (PMID: 24040445) Cancer Res. 2012 May 1;72(9):2162-71. (PMID: 22549946) Nature. 2011 Oct 05;478(7368):197-203. (PMID: 21976023) Nat Immunol. 2010 Dec;11(12):1093-101. (PMID: 20953201) Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5262-70. (PMID: 17875754) Am J Clin Oncol. 2016 Feb;39(1):98-106. (PMID: 26558876) Cancer Cell. 2018 Apr 9;33(4):649-663.e4. (PMID: 29576375) PLoS One. 2014 Feb 03;9(2):e87705. (PMID: 24498358) Oncol Lett. 2019 Feb;17(2):2365-2369. (PMID: 30719112) Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80. (PMID: 20160101) Am J Transplant. 2004 Oct;4(10):1614-27. (PMID: 15367216) Cell Biosci. 2018 Apr 18;8:30. (PMID: 29713453) Expert Opin Ther Targets. 2014 Nov;18(11):1265-75. (PMID: 25256399) Clin Immunol. 2010 Jun;135(3):466-75. (PMID: 20181533) J Immunol. 2017 Feb 1;198(3):986-992. (PMID: 28115587) Clin Cancer Res. 2014 Oct 15;20(20):5290-301. (PMID: 24691018) Cancer Cell. 2012 Mar 20;21(3):309-22. (PMID: 22439926) Cancer Immunol Immunother. 2014 Feb;63(2):81-99. (PMID: 24263240) J Immunol. 2015 Oct 15;195(8):3665-74. (PMID: 26363058) J Immunother. 2001 Sep-Oct;24(5):392-407. (PMID: 11696695) J Exp Med. 2013 Aug 26;210(9):1685-93. (PMID: 23897982) Cancer Microenviron. 2015 Dec;8(3):201-7. (PMID: 25385463) J Immunol. 2010 Jun 1;184(11):6545-51. (PMID: 20421648) Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):497-504. (PMID: 9641494) J Clin Invest. 2003 Oct;112(7):1116-24. (PMID: 14523048) Br J Cancer. 2017 Nov 21;117(11):1644-1655. (PMID: 29016555) Nat Med. 2011 Nov 07;17(11):1359-70. (PMID: 22064426) Int J Cancer. 2008 May 15;122(10):2286-93. (PMID: 18224687) J Leukoc Biol. 2013 Jul;94(1):41-53. (PMID: 23667165) J Immunother Cancer. 2018 Jun 20;6(1):61. (PMID: 29921320) Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):549-54. (PMID: 7549813) J Immunol. 2009 Feb 1;182(3):1746-55. (PMID: 19155524) PLoS One. 2011;6(8):e23522. (PMID: 21858153) Immunity. 2013 Jul 25;39(1):61-73. (PMID: 23890064) Pharmacol Ther. 2015 Mar;147:22-31. (PMID: 25444759) Int Immunopharmacol. 2017 Jun;47:70-77. (PMID: 28365507) Nature. 2011 Jul 13;475(7355):226-30. (PMID: 21753853) J Cell Physiol. 2011 Oct;226(10):2691-701. (PMID: 21302279) Cancer Res. 2012 Mar 1;72(5):1092-102. (PMID: 22282655) Cancer Immunol Immunother. 2019 Feb;68(2):221-232. (PMID: 30357458) J Immunol. 2011 Apr 1;186(7):4388-95. (PMID: 21357259) Front Immunol. 2015 Dec 17;6:639. (PMID: 26734006) Immunity. 2008 Mar;28(3):402-13. (PMID: 18328743) Clin Cancer Res. 2009 Apr 1;15(7):2231-7. (PMID: 19318474) Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917. (PMID: 29581255) ISRN Mol Biol. 2012 Dec 24;2012:381428. (PMID: 27340590) Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3058-63. (PMID: 20133667) Dis Esophagus. 2010 Jul;23(5):422-9. (PMID: 20002703) Nat Med. 2004 Sep;10(9):942-9. (PMID: 15322536) Cell Rep. 2014 Mar 27;6(6):992-999. (PMID: 24630990) Cells. 2019 Jun 18;8(6):. (PMID: 31216755) Br J Cancer. 2005 Jan 31;92(2):305-11. (PMID: 15655551) Oncotarget. 2014 Sep 30;5(18):8136-46. (PMID: 25327557) Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. (PMID: 16344461) Cancer Res. 2011 Aug 15;71(16):5522-5534. (PMID: 21742774) Eur J Immunol. 2004 Mar;34(3):623-630. (PMID: 14991591) Clin Cancer Res. 2010 Aug 15;16(16):4105-12. (PMID: 20682706) J Immunol. 2017 Feb 1;198(3):981-985. (PMID: 28115586) Sci Immunol. 2018 Sep 14;3(27):. (PMID: 30217811) Curr Top Microbiol Immunol. 2011;344:269-78. (PMID: 21086108) Immunol Res. 2011 Dec;51(2-3):170-82. (PMID: 22139852) Semin Cancer Biol. 2012 Aug;22(4):327-34. (PMID: 22465232) J Biol Chem. 2010 Mar 5;285(10):7176-86. (PMID: 19858205) Immunity. 2016 Feb 16;44(2):355-67. (PMID: 26872699) Immunity. 2009 May;30(5):636-45. (PMID: 19464986) Eur J Cancer. 2009 Aug;45(12):2123-31. (PMID: 19398324) Int J Cancer. 2013 Sep 15;133(6):1489-96. (PMID: 23447383) Immunity. 2000 Apr;12(4):431-40. (PMID: 10795741) Clin Exp Pharmacol Physiol. 2018 Oct;45(10):1002-1009. (PMID: 29905955) Front Immunol. 2018 Oct 26;9:2506. (PMID: 30416507) Br J Cancer. 2011 Jul 26;105(3):413-9. (PMID: 21730981) Cancer Immunol Immunother. 2009 Sep;58(9):1363-73. (PMID: 19172271) Immunology. 2008 Dec;125(4):450-8. (PMID: 19128356) Immunity. 2015 Feb 17;42(2):216-226. (PMID: 25692699) J Clin Invest. 2013 Nov;123(11):4859-74. (PMID: 24216477) Immunity. 2004 Oct;21(4):589-601. (PMID: 15485635) J Leukoc Biol. 2011 Jan;89(1):85-91. (PMID: 20952660) Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. (PMID: 25918390) J Immunol. 2008 May 1;180(9):5916-26. (PMID: 18424711) J Immunol. 2009 Sep 15;183(6):3720-30. (PMID: 19692638) Eur J Immunol. 2013 Sep;43(9):2421-9. (PMID: 23722868) Nat Immunol. 2007 Dec;8(12):1353-62. (PMID: 17982458) N Engl J Med. 2013 Jul 11;369(2):122-33. (PMID: 23724867) Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54. (PMID: 17671115) Sci Rep. 2015 Oct 14;5:15179. (PMID: 26462617) Oncol Res. 2013;20(7):303-17. (PMID: 23879171) Oncotarget. 2017 Nov 01;8(64):107844-107858. (PMID: 29296206) Trends Pharmacol Sci. 2018 Mar;39(3):307-325. (PMID: 29254698) Cancer Res. 2012 Sep 1;72(17):4351-60. (PMID: 22798340) Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. (PMID: 30054281) Eur J Immunol. 2009 Nov;39(11):3147-59. (PMID: 19688742) Cent Eur J Immunol. 2014;39(1):109-15. (PMID: 26155110) J Exp Med. 2013 Aug 26;210(9):1695-710. (PMID: 23897981) Cancer Res. 2011 Apr 15;71(8):2892-900. (PMID: 21292811) Cytokine Growth Factor Rev. 2015 Dec;26(6):615-23. (PMID: 26271893) J Immunol. 2013 Aug 1;191(3):1136-43. (PMID: 23817420) J Biol Chem. 2015 Nov 6;290(45):27158-27167. (PMID: 26408197) Oncoimmunology. 2015 Dec 10;5(3):e1090075. (PMID: 27141347) J Immunol. 2012 Dec 15;189(12):5602-11. (PMID: 23152559) Cell. 2013 Dec 5;155(6):1282-95. (PMID: 24315098) Curr Opin Oncol. 2013 Jan;25(1):76-84. (PMID: 23197193) Cancer Immunol Immunother. 2008 Jan;57(1):123-31. (PMID: 17522861) J Immunol. 2010 Apr 1;184(7):3433-41. (PMID: 20181882) J Exp Med. 2009 Dec 21;206(13):3015-29. (PMID: 20008522) Curr Opin Oncol. 2013 Nov;25(6):637-45. (PMID: 24076584) PLoS One. 2014 Jan 09;9(1):e85398. (PMID: 24416401) Sci Rep. 2015 Jan 14;5:7767. (PMID: 25586548) Nature. 2007 Nov 22;450(7169):566-9. (PMID: 18033300) Sci Immunol. 2019 May 31;4(35):. (PMID: 31152091) Front Immunol. 2013 Nov 25;4:405. (PMID: 24324469) J Exp Med. 2012 Oct 22;209(11):2001-16. (PMID: 23045606) Cell Death Differ. 2010 Apr;17(4):616-23. (PMID: 20075940) Am J Physiol Cell Physiol. 2011 Aug;301(2):C530-9. (PMID: 21593451) Immunology. 2008 Jan;123(1):129-38. (PMID: 18028372) Nat Immunol. 2005 Nov;6(11):1071-2. (PMID: 16239920) Immunol Res. 2011 Oct;51(1):71-9. (PMID: 21918886) Ann N Y Acad Sci. 2018 Apr;1417(1):104-115. (PMID: 29566262) Cancer Immun. 2013;13:5. (PMID: 23390376) Neoplasia. 2004 Sep-Oct;6(5):603-10. (PMID: 15548370) Cancer J. 2010 Jul-Aug;16(4):354-9. (PMID: 20693847) Cancer Lett. 2014 Apr 28;346(1):6-16. (PMID: 24333723) Hum Immunol. 2014 Jan;75(1):29-33. (PMID: 24121041) Clin Cancer Res. 2013 Oct 1;19(19):5300-9. (PMID: 24089443) J Immunol. 2017 Feb 15;198(4):1503-1511. (PMID: 28053234) J Cell Sci. 2006 Dec 15;119(Pt 24):5011-4. (PMID: 17158907) J Hepatol. 2016 Nov;65(5):944-952. (PMID: 27245433) Cancer Invest. 2013 Jun;31(5):330-5. (PMID: 23614656) |
| معلومات مُعتمدة: | R01 CA184728 United States CA NCI NIH HHS; R01 HL135325 United States HL NHLBI NIH HHS; R21 CA202358 United States CA NCI NIH HHS; T32 CA154274 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: Treg; anti-tumor immunity; immunosuppression; metastasis; tumor microenvironment |
| المشرفين على المادة: | 0 (Biomarkers) 0 (Ligands) |
| تواريخ الأحداث: | Date Created: 20191105 Date Completed: 20201109 Latest Revision: 20240721 |
| رمز التحديث: | 20240721 |
| مُعرف محوري في PubMed: | PMC6803384 |
| DOI: | 10.3389/fimmu.2019.02453 |
| PMID: | 31681327 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2019.02453 |